HRTX

HTX-019-202 - CINVANTI® (aprepitant) | GUARDS-1

COVID-19

Stage (next event)

Expected Date

Phase 2

TBD

Catalyst Info & Data Links

TITLE:  HTX-019-202 - CINVANTI® (aprepitant) Treatment in COVID-19

  • ClinicalTrial.gov (NCT04470622): Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)


WHAT IS THE CATALYST EVENT?

  • TBD


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD


PRIOR DATA/EVENTS

PRESS RELEASE

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors. Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis.



Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Amp Core Q2 '19 Report

HRTX Opioid-Free Pain Med Candidate Continues to Impress

Amp Mid-Q1 '19 Update

HRTX Mid-Q1 '19 Update

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon